검색
Vyne Therapeutics Inc
VYNE관심 목록에 추가
28.560USD
0.0000.00%
시장 운영 시간 （ET）
110.85M시가총액
손실P/E TTM
Vyne Therapeutics Inc 정보 회사
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc 프로필
종목 코드 VYNE
회사 이름Vyne Therapeutics Inc
상장일Jan 25, 2018
CEODomzalski (David)
직원 수13
유형Ordinary Share
회계 연도 종료Jan 25
주소685 Route 202/206 N., Suite 301
도시BRIDGEWATER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호08807
전화18007757936
웹사이트https://vynetherapeutics.com/
종목 코드 VYNE
상장일Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
Dr. Rebecca Velez Frey, Pharm.D.
Dr. Rebecca Velez Frey, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lori Payton, Ph.D.
Dr. Lori Payton, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Rachael Alford, Ph.D.
Dr. Rachael Alford, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
자주 묻는 질문
Vyne Therapeutics Inc의 상위 5대 주주는 누구인가요?
Vyne Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Tyler Zeronda
Vyne Therapeutics Inc(VYNE)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Vyne Therapeutics Inc의 주식을 보유한 기관은 총 92곳이며, 이들이 보유한 주식의 총 가치는 약 11.08M로 전체 발행 주식의 33.26%를 차지합니다. 이는 2025Q4 대비 -1672969.00 증가한 수치입니다.